Enigma Biomedical USA, Inc. (EB USA) today announced that it has selected two (2) four-repeat tau (4R Tau) protein PET imaging biomarkers to advance into Phase 1 (Ph1) studies. Previously, EB USA ...
four-repeat tau (4R Tau) protein PET imaging biomarkers to advance into Phase 1 (Ph1) studies. Previously, EB USA executed an Exclusive License and Option Agreement (License) with AbbVie for the ...
A new study has found faster accumulation of tau -- a key indicator of Alzheimer's disease -- in the brains of women over the age of 70 who took menopausal hormone therapy (HT) more than a decade ...
A new study has found that women with high levels of β-amyloid (Aβ), a protein linked to Alzheimer’s disease, experience ...
6don MSN
For the first time, scientists say, they have evidence that using a biologic drug to remove sticky beta amyloid plaques from ...
When we last looked at Lantheus in May, its stock was trading just under $80 a share. As a reminder, Lantheus Holdings, Inc.
Enigma Biomedical USA Inc. has selected two four-repeat tau (4R tau) protein PET imaging biomarkers to advance into phase I studies. These imaging biomarkers show promise as important new tools in ...
This article delves into the theoretical roles of these peptides in brain research and discusses the directions in which they ...
Simufilam did not show a significant reduction in co-primary endpoints of cognitive or functional decline versus placebo in patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback